Log In
Print
BCIQ
Print
Print this Print this
 

TD139

  Manage Alerts
Collapse Summary General Information
Company Galecto Biotech AB
DescriptionGalectin-3 (LGALS3) inhibitor
Molecular Target Galectin-3 (LGALS3)
Mechanism of ActionGalectin-3 antagonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today